{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:47:29Z","timestamp":1785235649713,"version":"3.55.0"},"reference-count":57,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The treatment of primary immunodeficiency disorders with allogeneic hematopoietic cell transplantation (HCT) has a history dating back to 1968 with the first successful transplant for a patient with severe combined immunodeficiency (SCID). The omission of conditioning for patients with SCID owing to their inability to reject allogeneic grafts and the increasing use of reduced intensity conditioning regimens often result in a state of mixed or split donor-recipient chimerism. The use of gene therapy (GT) via retroviral or lentiviral transduction of autologous CD34+ hematopoietic stem and progenitor cells is expected to correct only a portion of the hematopoietic stem cell compartment. The consequences of partial correction after either form of cellular therapy differ according to how the genetic deficiency affects immune cell development and function. Moreover, the conditioning regimen or lack thereof impacts the cell lineages at risk of partial correction. Advances in our understanding of immune reconstitution after HCT and GT for SCID, Wiskott\u2013Aldrich syndrome, and chronic granulomatous disease are discussed.<\/jats:p>","DOI":"10.1182\/hematology.2019000052","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:14:45Z","timestamp":1575627285000},"page":"457-465","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of primary immunodeficiency with allogeneic transplant and gene therapy"],"prefix":"10.1182","volume":"2019","author":[{"given":"Sung-Yun","family":"Pai","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology-Oncology, Department of Pediatrics, Boston Children\u2019s Hospital, Boston, MA;"},{"name":"Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; and"},{"name":"Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019120610105566100_B1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10875-017-0464-9","article-title":"International Union of Immunological Societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity","volume":"38","author":"Picard","year":"2018","journal-title":"J Clin Immunol"},{"issue":"4","key":"2019120610105566100_B2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood.V57.4.692.692","article-title":"Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide","volume":"57","author":"Kapoor","year":"1981","journal-title":"Blood"},{"issue":"7583","key":"2019120610105566100_B3","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0140-6736(68)92673-1","article-title":"Immunological reconstitution of sex-linked lymphopenic immunological deficiency","volume":"2","author":"Gatti","year":"1968","journal-title":"Lancet"},{"issue":"2","key":"2019120610105566100_B4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.V61.2.341.341","article-title":"Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells","volume":"61","author":"Reisner","year":"1983","journal-title":"Blood"},{"issue":"7","key":"2019120610105566100_B5","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJM199902183400703","article-title":"Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency","volume":"340","author":"Buckley","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"2019120610105566100_B6","first-page":"65","article-title":"Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis","volume":"3","author":"Small","year":"1997","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2019120610105566100_B7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbmt.2017.11.020","article-title":"Antithymocyte globulin: steps toward individualized dosing","volume":"24","author":"Admiraal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019120610105566100_B8","article-title":"Population pharmacokinetics of alemtuzumab (campath) in pediatric hematopoietic cell transplantation: towards individualized dosing to improve outcome [published online ahead of print 27 May 2019]","author":"Admiraal","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2019120610105566100_B9","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-018-0715-9","article-title":"Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation","volume":"58","author":"Langenhorst","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"2019120610105566100_B10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2019120610105566100_B11","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.bbmt.2018.10.013","article-title":"Innate immune recovery predicts CD4+ T cell reconstitution after hematopoietic cell transplantation","volume":"25","author":"de Koning","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5644","key":"2019120610105566100_B12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"9","key":"2019120610105566100_B13","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"issue":"15","key":"2019120610105566100_B14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified \u03b3-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2019120610105566100_B15","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"issue":"5577","key":"2019120610105566100_B16","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"issue":"97","key":"2019120610105566100_B17","first-page":"97ra80","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction [published correction appears in Sci Transl Med. 2013 5(168):168er1]","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"key":"2019120610105566100_B18","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019120610105566100_B19","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1172\/JCI90367","article-title":"Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency","volume":"127","author":"Shaw","year":"2017","journal-title":"J Clin Invest"},{"issue":"19","key":"2019120610105566100_B20","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2016-12-756734","article-title":"Cytoreductive conditioning intensity predicts clonal diversity in ADA-SCID retroviral gene therapy patients","volume":"129","author":"Cooper","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019120610105566100_B21","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","volume":"126","author":"Gennery","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"17","key":"2019120610105566100_B22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood-2018-03-840702","article-title":"SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery","volume":"132","author":"Haddad","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2019120610105566100_B23","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2017-05-781849","article-title":"Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study","volume":"130","author":"Heimall","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2019120610105566100_B24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2019120610105566100_B25","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jpeds.2009.07.049","article-title":"Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis","volume":"155","author":"Railey","year":"2009","journal-title":"J Pediatr"},{"issue":"1","key":"2019120610105566100_B26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2018.08.027","article-title":"The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018)","volume":"143","author":"Dvorak","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2019120610105566100_B27","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaci.2015.08.022","article-title":"Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells","volume":"137","author":"Wiekmeijer","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2019120610105566100_B28","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fimmu.2017.00798","article-title":"Natural killer cells from patients with recombinase-activating gene and non-homologous end joining gene defects comprise a higher frequency of CD56bright NKG2A+++ cells, and yet display increased degranulation and higher perforin content","volume":"8","author":"Dobbs","year":"2017","journal-title":"Front Immunol"},{"issue":"2","key":"2019120610105566100_B29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019120610105566100_B30","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jaci.2015.04.027","article-title":"Radiation-sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation--what to do?","volume":"136","author":"Cowan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"suppl 1","key":"2019120610105566100_B31","first-page":"S42","article-title":"Autologous ex vivo lentiviral gene therapy for the treatment of severe combined immune deficiency due to adenosine deaminase deficiency","volume":"39","author":"Kohn","year":"2019","journal-title":"J Clin Immunol"},{"issue":"26","key":"2019120610105566100_B32","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1182\/blood-2017-10-809822","article-title":"B-cell differentiation and IL-21 response in IL2RG\/JAK3 SCID patients after hematopoietic stem cell transplantation","volume":"131","author":"Miggelbrink","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019120610105566100_B33","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa1000164","article-title":"Efficacy of gene therapy for X-linked severe combined immunodeficiency","volume":"363","author":"Hacein-Bey-Abina","year":"2010","journal-title":"N Engl J Med"},{"issue":"97","key":"2019120610105566100_B34","doi-asserted-by":"crossref","first-page":"97ra79","DOI":"10.1126\/scitranslmed.3002715","article-title":"Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci Transl Med"},{"issue":"335","key":"2019120610105566100_B35","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"issue":"16","key":"2019120610105566100_B36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2019120610105566100_B37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.iac.2010.02.001","article-title":"Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: advances in biology and future directions for treatment","volume":"30","author":"Pai","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"2019120610105566100_B38","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood"},{"issue":"6148","key":"2019120610105566100_B39","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"issue":"15","key":"2019120610105566100_B40","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Hacein-Bey Abina","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"2019120610105566100_B41","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1084\/jem.20110200","article-title":"WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity","volume":"208","author":"Becker-Herman","year":"2011","journal-title":"J Exp Med"},{"key":"2019120610105566100_B42","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaci.2015.08.010","article-title":"Broad spectrum of autoantibodies in patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia","volume":"136","author":"Crestani","year":"2015","journal-title":"J Allergy Clin. Immunol."},{"issue":"12","key":"2019120610105566100_B43","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2011-09-379412","article-title":"B cell-intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice","volume":"119","author":"Recher","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019120610105566100_B44","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/eji.201344245","article-title":"Exacerbated experimental arthritis in Wiskott-Aldrich syndrome protein deficiency: modulatory role of regulatory B cells","volume":"44","author":"Bouma","year":"2014","journal-title":"Eur J Immunol"},{"issue":"6","key":"2019120610105566100_B45","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/sji.12282","article-title":"Effects of Wiskott-Aldrich syndrome protein deficiency on IL-10-producing regulatory B cells in humans and mice","volume":"81","author":"Du","year":"2015","journal-title":"Scand J Immunol"},{"issue":"1","key":"2019120610105566100_B46","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41467-018-03670-6","article-title":"WASP-mediated regulation of anti-inflammatory macrophages is IL-10 dependent and is critical for intestinal homeostasis","volume":"9","author":"Biswas","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2019120610105566100_B47","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41467-017-01676-0","article-title":"Wiskott-Aldrich syndrome protein regulates autophagy and inflammasome activity in innate immune cells","volume":"8","author":"Lee","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"2019120610105566100_B48","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jaci.2017.12.1000","article-title":"Autonomous role of Wiskott-Aldrich syndrome platelet deficiency in inducing autoimmunity and inflammation","volume":"142","author":"Sereni","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2019120610105566100_B49","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019120610105566100_B50","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol"},{"issue":"9915","key":"2019120610105566100_B51","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet"},{"key":"2019120610105566100_B52","article-title":"Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT [published online ahead of print 2 August 2019]","author":"Marsh","journal-title":"J Clin Immunol"},{"issue":"1","key":"2019120610105566100_B53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2019120610105566100_B54","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm1393","article-title":"Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1","volume":"12","author":"Ott","year":"2006","journal-title":"Nat Med"},{"issue":"4","key":"2019120610105566100_B55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2174\/1566523215666150515145255","article-title":"Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD\u2014importance of timing","volume":"15","author":"Siler","year":"2015","journal-title":"Curr Gene Ther"},{"issue":"1","key":"2019120610105566100_B56","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/mt.2010.226","article-title":"Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells","volume":"19","author":"Santilli","year":"2011","journal-title":"Mol Ther"},{"issue":"suppl 1","key":"2019120610105566100_B57","first-page":"S45","article-title":"Lentiviral vector gene therapy for X-linked chronic granulomatous disease corrects neutrophil function","volume":"39","author":"Malech","year":"2019","journal-title":"J Clin Immunol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/457\/1546234\/hem2019000052c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2019\/1\/457\/1546234\/hem2019000052c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T10:15:11Z","timestamp":1575627311000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2019\/1\/457\/422633\/Treatment-of-primary-immunodeficiency-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,6]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2019000052","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,6]]}}}